Which of the following statements best reflects standard breast cancer management?

Which of the following statements best reflects standard breast cancer management?

• A. Surgical resection sparing as much breast tissue possible (lumpectomy vs mastectomy) plus axillary lymph node dissection; may include neoadjuvant therapy; adjuvant radiation and systemic therapy; bisphosphonates
• B. Only lumpectomy without adjuvant therapy
• C. Radiation therapy alone is sufficient
• D. Immunotherapy alone is curative

Answer: (A)

Treating breast cancer effectively relies on a combination of local control and systemic management. The standard approach starts with removing the tumor through surgery, choosing breast-conserving options (sparing as much breast tissue as possible) or mastectomy based on tumor size, location, and patient factors, while also evaluating the axillary lymph nodes to stage the disease. Neoadjuvant therapy may be used to shrink larger tumors before surgery, increasing the chance of breast-conserving surgery. After surgery, adjuvant radiation targets any remaining microscopic disease in the breast or chest wall to reduce local recurrence and can be indicated after mastectomy in higher-risk cases. Systemic therapy—such as endocrine therapy for hormone receptor–positive cancers, chemotherapy for higher-risk disease, and targeted therapies when appropriate—addresses micrometastatic disease and improves survival. Bisphosphonates or other bone-modifying agents are added for bone health and to reduce skeletal-related events in suitable patients, especially in postmenopausal women or those with bone involvement. Put together, this integrated, multimodal strategy reflects current standard breast cancer management. Choosing therapy that relies on a single modality, like surgery alone without adjuvant therapy, or radiation therapy alone, or immunotherapy alone, does not address either residual local disease, nodal involvement, or systemic micrometastases, and is not consistent with how breast cancer is best managed.

Treating breast cancer effectively relies on a combination of local control and systemic management. The standard approach starts with removing the tumor through surgery, choosing breast-conserving options (sparing as much breast tissue as possible) or mastectomy based on tumor size, location, and patient factors, while also evaluating the axillary lymph nodes to stage the disease. Neoadjuvant therapy may be used to shrink larger tumors before surgery, increasing the chance of breast-conserving surgery. After surgery, adjuvant radiation targets any remaining microscopic disease in the breast or chest wall to reduce local recurrence and can be indicated after mastectomy in higher-risk cases. Systemic therapy—such as endocrine therapy for hormone receptor–positive cancers, chemotherapy for higher-risk disease, and targeted therapies when appropriate—addresses micrometastatic disease and improves survival. Bisphosphonates or other bone-modifying agents are added for bone health and to reduce skeletal-related events in suitable patients, especially in postmenopausal women or those with bone involvement. Put together, this integrated, multimodal strategy reflects current standard breast cancer management.

Choosing therapy that relies on a single modality, like surgery alone without adjuvant therapy, or radiation therapy alone, or immunotherapy alone, does not address either residual local disease, nodal involvement, or systemic micrometastases, and is not consistent with how breast cancer is best managed.